CVS Health Corporation (CVS) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in CVS Health (CVS) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. The thesis is integrated healthcare: CVS is one of the only companies that owns a retail pharmacy chain, the Caremark pharmacy benefit manager, and the Aetna health insurer under one roof, and bulls see a turnaround under CEO David Joyner restoring margins while the stock trades cheaply (about 11x forward earnings) with a ~2.9% dividend yield. The single biggest risk is the medical-cost trend at Aetna, where rising claims can compress earnings faster than management can re-price, layered on top of regulatory scrutiny of the PBM business, opioid litigation and execution risk. As of October 16, 2026 the shares were about $93, up roughly 16% year to date but down about 16% over the past three months.
CVS stock price
As of 2026-11-16, CVS Health Corporation (CVS) last closed at $88.59, up 13.0% over the past year. Over the past 52 weeks it has traded between $70.08 and $110.60.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or CVS Health Corporation's investor relations page. Walnut is informational, not investment advice.
CVS key stats
At $88.59 on November 16, 2026, CVS Health Corporation (CVS) has a market cap of $113B, a P/E of 10.3 on trailing earnings (10.3 on forward earnings) and a dividend yield of 3.00%.
- Market cap
- $113B
- P/E (trailing)
- 10.3
- P/E (forward)
- 10.3
- EPS (trailing 12 months)
- $8.61
- Price to book
- 1.4
- Dividend yield
- 3.00%
- Beta
- 0.58
Market cap, P/E and yield are measured at the $88.59 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with CVS Health Corporation (CVS)?
The last two weeks for CVS Health Corporation, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- CVS closed at $88.59 on November 16, 2026, up 3.9% over the past five trading days (from $85.25).
- On November 4, 2026, CVS Health Corporation filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 4, 2026, CVS Health Corporation filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
- On November 4, 2026, CVS Health Corporation filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 6, 2026, UBS lowered its target to $107.00 from $118.00 (Buy).
- On November 5, 2026, Leerink Partners lowered its target to $104.00 from $112.00 (Outperform).
- On November 5, 2026, Barclays lowered its target to $107.00 from $108.00 (Overweight).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
CVS Health Corporation (CVS) latest quarter
CVS Health reported revenue of $108.4 billion for Q3 2026, up 5% from a year earlier (CVS Health, Nov 4, 2026).
Source: CVS Health Q3 2026 results, Nov 4, 2026. Full earnings breakdown
What does CVS Health Corporation (CVS) do?
CVS Health runs three reporting segments. Health Care Benefits is the Aetna insurance business, which earns premiums from roughly 26 million medical members and profits when claims (the medical benefit ratio) stay below what it collects. Health Services is built around the Caremark pharmacy benefit manager, which negotiates drug prices and manages pharmacy claims for health plans and employers and generated over $48 billion of revenue in Q1 2026. Pharmacy and Consumer Wellness is the familiar retail footprint of CVS drugstores, which makes money filling prescriptions and selling front-of-store health and consumer goods, with same-store prescription volumes up nearly 7% in Q1 2026.
The modern shape of the company traces to its 2018 acquisition of Aetna for roughly $70 billion, which combined a national insurer with the existing pharmacy and PBM businesses and added substantial debt. After a difficult stretch in 2023 and 2024 when Aetna's medical costs ran well above plan and the stock fell sharply, David Joyner became CEO in October 2024 and was later named board chair; he has framed the recovery as restoring pricing discipline at Aetna while running the integrated model more tightly. Total revenue over the twelve months to June 2026 was about $413 billion, among the largest of any U.S. company, with Q2 2026 revenue of about $106 billion, up about 7% year over year. Margins are thin by design at that scale: trailing net income was about $4.9 billion, a net margin near 1.2%.
What's driving CVS Health Corporation (CVS)?
Integrated model under one roof
CVS is one of few companies that combines an insurer (Aetna), a pharmacy benefit manager (Caremark), and a retail pharmacy chain. Bulls argue this vertical integration lets it capture margin across the drug-spending chain and steer members toward its own assets. When the pieces work together, the model can be more resilient than any single-segment competitor.
Turnaround and improving Aetna margins
After Aetna's medical costs ran far above plan in 2023 and 2024, management has reported several consecutive quarters of improvement. In Q1 2026 the medical benefit ratio fell to ~84.6% from ~87.3% a year earlier, and CVS raised its full-year 2026 adjusted EPS guidance to ~$7.30 to $7.50. Q2 2026 followed with adjusted EPS of $2.58 against a $1.85 estimate, the fourth straight quarterly beat, and analysts' full-year 2026 estimate has since moved up to about $8.04, with about $8.54 expected for 2027.
Low valuation versus the broad market
CVS trades at a low forward earnings multiple relative to the S&P 500, a sign of investor caution after the prior downturn. At about $93 a share in October 2026 and forward EPS estimates near $8.54, the forward multiple is about 11x, lower than the mid-teens it carried in June when the shares were near $104 and guidance was lower. Value-oriented investors see this as pricing in continued trouble that the recent results have started to challenge; the 25 analysts Yahoo Finance tracks have a mean target near $115.
Dividend and cash generation
CVS pays a quarterly dividend of ~$0.665 per share, or roughly $2.66 annually, for a yield around 2.9% at an October 2026 price near $93. The company held about $14 billion of cash, generated about $14.8 billion of operating cash flow and about $8.1 billion of free cash flow over the trailing twelve months. Income-focused investors weigh that payout against a debt load of about $76 billion.
What are the risks to CVS Health Corporation (CVS)?
The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. The Caremark PBM faces intensifying regulatory and political pressure, including FTC litigation, a 2026 House Judiciary antitrust report, state investigations in Florida and elsewhere, and rebate pass-through reform that could compress a core profit pool. Legal costs continue: in October 2026 CVS agreed to a $315 million settlement of federal claims over opioid dispensing, with new controlled-substance oversight measures. The retail pharmacy business faces reimbursement pressure and store closures, and the company carries about $76 billion of debt, much of it from the Aetna deal, which limits flexibility if the turnaround stalls.
What is the CVS Health Corporation (CVS) forecast?
25 analysts publish price targets on CVS, averaging $110.32 as of November 2026, or +24.5% against the $88.59 share price on November 16, 2026. The published targets run from $86.00 to $146.00, a moderate spread, and the ratings split 25 buy, 3 hold, 0 sell. Over the last six months there have been 6 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full CVS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is CVS a buy or a sell?
We give no verdict on CVS Health Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Integrated model under one roof. CVS is one of few companies that combines an insurer (Aetna), a pharmacy benefit manager (Caremark), and a retail pharmacy chain. The most optimistic published target, $146.00, assumes this works close to its best case.
The case against. The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. The most pessimistic target, $86.00, is roughly what CVS is worth if this bites instead.
Read the full bull and bear case on CVS, including what would have to change to break either one. Walnut is not an investment adviser.
Has CVS Health Corporation (CVS) split its stock?
No. CVS Health Corporation (CVS) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is CVS Health Corporation (CVS) valued?
Market cap, P/E and dividend yield at today's price are in the CVS key stats above. The business figures below come from CVS Health Corporation's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$413 billion (Q2 2026 ~$106B, up ~7% YoY)
- Adjusted EPS: Q2 2026 $2.58 vs $1.85 estimate; 2026 consensus ~$8.04, 2027 ~$8.54
- Net income (TTM): ~$4.9 billion (net margin ~1.2%)
- Aetna medical benefit ratio (Q1 2026): ~84.6%, improved from ~87.3% a year earlier
- Debt / cash: ~$76 billion debt, ~$14 billion cash
As of October 2026: CVS trades near 11x forward earnings and about 0.3x sales, a low multiple versus the broad market that reflects lingering caution after the 2023 to 2024 Aetna downturn and continuing PBM and legal risk rather than current results, which have beaten estimates four quarters running. Q3 2026 results are scheduled for November 4, 2026, with consensus adjusted EPS near $1.65 on ~$105 billion of revenue. Figures are approximate and tied to the asOf date; verify live quotes and the latest filings before acting.
Which ETFs hold CVS Health Corporation (CVS)?
If you want CVS exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.
| ETF | Name | % in CVS | Expense ratio | |
|---|---|---|---|---|
| RWL | Invesco S&P 500 Revenue ETF | 1.9% | 0.39% |
What themes does CVS Health Corporation (CVS) fit?
These are the investment theses CVS naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.
Who competes with CVS Health Corporation (CVS)?
Integrated insurer and PBM (UnitedHealth)
UnitedHealth Group is the closest structural peer, pairing the UnitedHealthcare insurer with the Optum PBM and care-delivery arm. It is larger and historically higher-margin, and it competes with CVS across insurance, pharmacy benefits, and care services.
PBM and insurance (Cigna / Express Scripts)
Cigna owns Express Scripts, one of the three large pharmacy benefit managers alongside Caremark and OptumRx, plus a national insurance business. It competes directly with Caremark for plan-sponsor contracts and faces the same PBM reform scrutiny.
Retail pharmacy (Walgreens and others)
Walgreens Boots Alliance is the main retail drugstore rival, and grocery and big-box pharmacies plus mail-order and online players also compete for prescription volume. This segment faces reimbursement pressure and store closures across the industry.
Health insurers (Humana, Elevance, Centene)
On the Aetna side, CVS competes with Humana, Elevance Health, and Centene for Medicare Advantage, Medicaid, and commercial members. Medical-cost trends and Medicare rate decisions affect all of them at once.
What stocks are similar to CVS Health Corporation (CVS)?
Other names that sit close to CVS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in CVS Health Corporation (CVS)
There are three common ways to get CVS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (RWL), which spreads the position across many companies. Or build it into a focused thematic portfolio, so CVS sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where CVS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on CVS Health Corporation (CVS)
CVS today is a vertically integrated healthcare company whose results swing most on Aetna's medical costs and the pace of the Joyner-era turnaround. 2026 has shown the recovery taking hold in the numbers: Q1 adjusted EPS of $2.57 and Q2 of $2.58 both cleared estimates by a wide margin (Q2 consensus was $1.85), Aetna's medical benefit ratio improved to ~84.6% in Q1 from ~87.3% a year earlier, and analysts now expect full-year adjusted EPS of about $8.04, above the $7.30-7.50 guidance management gave in the spring. The stock has not kept pace with those upgrades over the past three months, and in October 2026 CVS agreed to pay $315 million to resolve federal opioid-dispensing claims. If you believe the integrated insurer-PBM-pharmacy model can earn durable margins again and that the low valuation reflects past problems more than future ones, the question becomes sizing and overlap with the rest of your portfolio, not timing; the risk is that medical costs reaccelerate, PBM reform compresses a core profit pool, or the roughly $76 billion debt load limits flexibility before the turnaround fully lands. Q3 results are due November 4, 2026.
More on CVS Health Corporation (CVS)
Whether CVS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CVS a buy or a sell?, and where the stock could go from here in the CVS stock forecast.
For income investors, whether CVS pays a dividend and how the payout looks is covered in does CVS pay a dividend? And to weigh CVS against a peer, read the full side-by-side comparisons: CVS vs PFE and CVS vs UNH.
Wondering how CVS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about CVS Health Corporation
Ask Walnut's AI anything about CVS and see how it fits what you own.
FAQ
Is CVS a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not advice. The bull case is a cheap valuation (about 11x forward earnings), a ~2.9% dividend yield, and an Aetna turnaround that has beaten earnings estimates four quarters in a row. The bear case is that medical costs could reaccelerate, PBM reform could compress profits, legal settlements keep coming, and debt is high. Both can be true at once.
What does CVS Health do?
+
CVS Health is an integrated healthcare company with three parts: Aetna, a health insurer covering roughly 26 million medical members; Caremark, a pharmacy benefit manager that negotiates drug prices for plans and employers; and CVS retail pharmacies that fill prescriptions and sell front-of-store goods. Combined revenue was about $413 billion over the twelve months to June 2026.
What is the CVS dividend yield?
+
CVS pays a quarterly dividend of about $0.665 per share, or roughly $2.66 per year. At a share price near $93 in October 2026, that works out to a yield of about 2.9%. Some sources report a slightly different figure depending on the price and calculation method. Dividends can be changed or suspended by the board at any time.
Why did CVS stock drop?
+
The sharp decline in 2023 and 2024 came mainly from Aetna's medical costs running well above plan, especially in Medicare Advantage, which forced earnings guidance cuts. Added pressure came from PBM regulatory scrutiny, retail reimbursement, and the large debt from the Aetna acquisition. Shares recovered as margins improved, reaching about $110 at their 52-week high, then fell about 16% over the three months to mid-October 2026 even as Q2 results beat estimates. They remain up about 16% for 2026.
How can I invest in CVS Health?
+
You can buy CVS shares or fractional shares at any major broker, hold it inside an ETF that includes it, or hold it as one position in a thematic basket alongside related names. Many healthcare and dividend-focused ETFs include CVS. Walnut lets you track CVS as part of a basket built around an integrated-healthcare or value thesis.
Which ETFs hold CVS Health?
+
CVS commonly appears in broad healthcare sector funds, in value-oriented funds, and in dividend-focused ETFs, as well as in total-market index funds that hold most large U.S. companies. The exact weight varies by fund. Check a specific ETF's published holdings to confirm CVS is included and to see how large the position is.
Is CVS a value stock or a growth stock?
+
CVS is generally viewed as a value stock. It trades at a low forward earnings multiple relative to the broad market, pays a dividend, and grows revenue slowly off a very large base rather than expanding quickly. The investment debate centers on margin recovery and regulatory risk rather than rapid top-line growth.
What is the biggest risk to CVS Health?
+
The single biggest swing factor is Aetna's medical-cost trend: if claims rise faster than premiums, profits fall quickly, as they did in 2023 and 2024. Close behind are regulatory and antitrust pressure on the Caremark PBM, reimbursement pressure in retail pharmacy, and a heavy debt load. These risks can compound during a downturn.
How did CVS Health do in its latest quarter?
+
In Q2 2026, CVS reported revenue of about $106.1 billion, up about 7% from a year earlier, net income of about $3.0 billion, and adjusted EPS of $2.58 against a $1.85 consensus. It was the fourth straight quarter above estimates. Q3 2026 results are scheduled for November 4, 2026, with consensus adjusted EPS of about $1.65.
How has CVS stock performed in 2026?
+
As of the October 16, 2026 close of about $92.86, CVS shares were up roughly 16% year to date and about 14% over one year, within a 52-week range of about $70 to $111. They have given back about 16% over the past three months. Past performance does not predict future returns.
What was the CVS $315 million opioid settlement?
+
In October 2026 CVS agreed to pay $315 million to resolve federal claims that its pharmacies filled opioid prescriptions in violation of US controlled-substances law, and agreed to new oversight measures including tighter monitoring of opioid dispensing. It adds to earlier opioid settlements and is one of the legal costs that sit alongside the Aetna and Caremark operating story.
Guides that feature CVS
CVS is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with CVS Health Corporation's investor relations page or your broker before making investment decisions.